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A membrane-based microfluidic device for controlling the flux of platelet
agonists into flowing blood
Abstract
The flux of platelet agonists into flowing blood is a critical event in thrombosis and hemostasis. However,
few in vitro methods exist for examining and controlling the role of platelet agonists on clot formation and
stability under hemodynamic conditions. In this paper, we describe a membrane-based method for
introducing a solute into flowing blood at a defined flux. The device consisted of a track-etched
polycarbonate membrane reversibly sealed between two microfluidic channels; one channel contained
blood flowing at a physiologically relevant shear rate, and the other channel contained the agonist(s). An
analytical model described the solute flux as a function of the membrane permeability and
transmembrane pressure. The model was validated using luciferase as a model solute for
transmembrane pressures of 50–400 Pa. As a proof-of-concept, the weak platelet agonist ADP was
introduced into whole blood flowing at 250 s-1 at three fluxes (1.5, 2.4, and 4.4 × 10-18 mol µm-2 s-1).
Platelet aggregation was monitored by fluorescence microscopy during the experiment and the
morphology of aggregates was determined by post hoc confocal and electron microscopy. At the lowest
flux (1.5 × 10-18 mol µm-2 s-1), we observed little to no aggregation. At the higher fluxes, we observed
monolayer (2.4 × 10-18 mol µm-2 s-1) and multilayer (4.4 × 10-18 mol µm-2 s-1) aggregates of platelets and
found that the platelet density within an aggregate increased with increasing ADP flux. We expect this
device to be a useful tool in unraveling the role of platelet agonists on clot formation and stability.
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The flux of platelet agonists into flowing blood is a critical event in thrombosis and hemostasis.
However, few in vitro methods exist for examining and controlling the role of platelet agonists on
clot formation and stability under hemodynamic conditions. In this report, we describe a
membrane-based method for introducing a solute into flowing blood at a defined flux. The device
consisted of a track-etched polycarbonate membrane reversibly sealed between two microfluidic
channels; one channel contained blood flowing at a physiologically relevant shear rate, and the
other channel contained the agonist(s). An analytical model described the solute flux as a function
of the membrane permeability and transmembrane pressure. The model was validated using
luciferase as a model solute for transmembrane pressures of 50-400 Pa. As a proof-of-concept, the
weak platelet agonist ADP was introduced into whole blood flowing at 250 sec-1 at three fluxes
(1.5, 2.4, and 4.4 × 10-18 mol μm-2 sec-1). Platelet aggregation was monitored by fluorescence
microscopy during the experiment and the morphology of aggregates was determined by post hoc
confocal and electron microscopy. At the lowest flux (1.5 × 10-18 mol μm-2 sec-1), we observed
little to no aggregation. At the higher fluxes, we observed monolayer (2.4 × 10-18 mol μm-2 sec-1)
and multilayer (4.4 × 10-18 mol μm-2 sec-1) aggregates of platelets and found that the platelet
density within an aggregate increased with increasing ADP flux. We expect this device to be a
useful tool in unraveling the role of platelet agonists on clot formation and stability.
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During thrombus formation on the exposed subendothelial
matrix, platelets pause or roll on von Willebrand factor, and
then arrest and activate on collagen1, 2. Adhered platelets
become activated through outside-in signaling via
glycoprotein receptors3. Activated platelets recruit and
aggregate other platelets by producing soluble agonists and
releasing them into the flowing blood. These agonists include,
but are not limited to, thrombin4, ADP5, and thromboxane A26.
The cellular and molecular events of platelet adhesion to
surface-bound proteins and subsequent platelet activation has
been extensively studied in animal7-9 and in vitro models10-14.
In vitro models have been critical in defining the shear
dependent bonding dynamics between platelet receptors and
their surface bound ligands. Parameters such as on and off
rates and adhesion efficiency have been measured by
manipulating the composition and density of surface-bound
ligands15. However, there are no in vitro models for
manipulating agonist flux into flowing blood.
In this report, we describe a membrane based microfluidic
device for controlling the flux of platelet agonists into flowing
whole blood. The device consists of two channels separated
by a membrane. One channel contains blood flowing at a
physiologically relevant mean wall shear rate (250-2000 sec1
). The second channel, containing the agonist(s), is oriented
perpendicular to the first channel. At the intersection of the
two channels, the flux of agonists into flowing blood is
controlled by the concentration of the agonist and the
This journal is © The Royal Society of Chemistry [year]
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transmembrane pressure. Luciferase was used as a model
solute to examine the roles of wall shear rate, the relative flow
rates of the two channels, and protein fouling on flux.
Analytical and numerical models were developed to describe
the fluid flow and mass transport in the device. As a proof-ofconcept, the platelet agonist ADP was introduced at three
different molar fluxes into flowing whole blood. Post hoc
electron and confocal microscopy reveal that platelet
activation and aggregation depend on the magnitude of ADP
flux. This is the first demonstration of user-controlled ADP
wall flux into flowing blood to trigger platelet deposition.

2. Experimental
2.1 Device fabrication and operation
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Figure 1a illustrates the three layers of the device; 1) a top
channel that contains flowing blood, 2) a track-etched
polycarbonate membrane, and 3) a bottom channel that
contains the agonist solution and a vacuum chamber. The
channels were made by (poly)dimethlysiloxane (PDMS)
molding techniques16. Briefly, a high aspect ratio negative
photoresist (KMPR 1050, MicroChem Corp., Newton, MA)
was spun and patterned on a silicon substrate at a height of
100 μm. Microfluidic channels had a cross-sectional area of
100 μm × 100 μm. In the bottom layer the channel was
separated by a solid barrier from the vacuum chamber. An
array of 400 μm posts spaced 1 mm apart was used to prevent
collapse of the vacuum chamber under negative pressure
(Figure 1c). The bottom channel was a single mold process,
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PDMS mold off of a photoresist master. The top channel and
vacuum chamber required a two mold process, with an
additional PDMS mold off a PDMS master. We found the two
mold process to provide better pattern transfer of the pillars
than a single mold process. Inlet and outlet holes were created
in the PDMS using sharpened 23 gauge stainless steel tubing.
Small diameter tubing (PEEK, ID=150 μm, OD=360 μm,
Upchurch Scientific, Oak Harbor, WA) was used to make
external connections to reservoirs of agonist(s) and blood
solutions and withdrawal syringes. A compression fitting for
connection to the PDMS was made by gluing a larger
diameter sleeve (PEEK, ID=380 μm, OD=1/16 inch) over the
end of the small diameter tubing. One foot of tubing was used
for all four connections, inlet and outlet of both channels. The
total dead volume in the tubing for each channel was 11 μL.
The flow rate of the top and bottom channels were
independently controlled with two syringe pumps (PHD 2000,
Harvard Apparatus, Holliston, MA) driving glass syringes
(100 μL and 250 μL, Hamilton Co. Reno, NV). The device
was assembled by placing a track-etched polycarbonate
membrane (13 mm diameter, B1013-MB, Structure Probe,
Inc., West Chester, PA) onto a 10 mm platform on the bottom
PDMS layer. The bottom and top layers were aligned by hand
using a low magnification stereoscope, brought into contact,
and vacuum sealed at a pressure of ~40 kPa using a diaphragm
pump (DOA-V163-BN, Gast Manufacturing, Inc., Benton
Harbor, MI). By design, there was a thin gap between the two
PDMS layers at the periphery of the membrane. During the
flow experiments, fluid slowly escaped through this gap into
the vacuum chamber. Less than 10 μL of fluid was lost
through the gap over one hour. Since the membrane area is
larger than the PDMS platform there is no crosscontamination between the two fluid streams. At high wall
shear rates (1000-2000 sec -1) both the blood and agonist
reservoirs were at atmospheric pressure and were withdrawn
(negative pressure) via the syringe pumps. In some
experiments at low all shear rates (250-500 sec-1), the agonist
solution was infused (positive pressure) and the blood solution
withdrawn (negative pressure) to a achieve higher
transmembrane pressure.
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2.2.1 Analytical Model of Agonist Flux
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where γwall is the mean wall shear rate, A is the channel
sectional area, f is the Fanning friction factor, and Re
Reynolds number based on a characteristic length of
find the transmembrane pressure, eq. 1 was evaluated
half length of both channels (including tubing):
ΔPmembrane = P1, L / 2 − P2, L / 2
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(1)

where P is pressure, L is channel length, v̄ is the mean
velocity, μ is viscosity, h is channel height, ε is the channel
aspect ratio. The mean velocity was set to achieve a desired
mean wall shear rate:
v=

2.2 Agonist flux models
Solute flux through the membrane into a flowing solution is
determined by the solute properties (size, shape, charge), the
pore characteristics of the membrane (radius, length, pore
density), and the operating conditions (concentration gradients
and pressure gradients). Within the blood containing channel,
the constant flux of agonist leads to the formation of a
boundary layer which begins at the upstream edge of the
reaction zone. The thickness of the boundary layer determines
how many platelets experience threshold concentrations of an
agonist and thus are activated. We developed two models to
capture each of these events; 1) an analytical model which
describe the flux of a solute through the membrane and 2) a
finite element model to capture the fluid dynamics and
transport within the microfluidic channels.

As a first-order estimate, we treated the membrane as a porous
medium that uniformly experiences the same pressure drop
across the entire length and width of the membrane (100 μm ×
100 μm) at the intersection between the two channels. The
transmembrane pressure was obtained by first calculating the
pressure in each channel and then subtracting the difference
between the two channels at the intersection point. Owing to
the small diameter of the PEEK tubing used in the
experiments, we also accounted for the pressure drop through
the tubing, which in some cases was a significant fraction of
the overall pressure drop. We analytical expressions to find
the pressure drop through a rectangular channel per unit
length and the wall shear rate17:

(2)

(3)

crossis the
A. To
at the
(4)

where ΔPmembrane is the transmembrane pressure, and P1,L/2 and
P2,L/2 is the pressure in channel 1 and 2, respectively, at the
half length of the channel. The specific discharge of agonist
from channel 2 into channel 1 was calculated using Darcy’s
law and the experimentally determined hydraulic permeability
(see section 2.3.1):
va = −

k ΔPmembrane
t

μ

(5)

where va is the agonist velocity through a single pore, k is the
Darcy’s permeability, and t is the membrane thickness. The
unhindered agonist flux was calculated by considering both
diffusive and convective transport through the membrane:
95

100

J a = − D∞ ∇c a + v a c a

(6)

where Ja is the agonist flux, D∞ is the agonist diffusion
coefficient in water, ca is the agonist concentration, and va is
the mean velocity. In the membranes used in this report the
agonist was much smaller than the pore (ragonist/rpore<0.01), so
there were no steric hindrances to transport18. We assume that

This journal is © The Royal Society of Chemistry [year]
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the concentration in the top channel is zero, so that the
concentration gradient across the membrane is ∇ca=(ca,2-0)/L.
This assumption overestimates the agonist flux because the
concentration at the wall in the top channel is nonzero.
However, in most cases the device is operated at a pore Peclet
number (Pe=vaL/D) greater than 10 and therefore the
contribution of the diffusive flux to the overall flux is small
(<10%).
2.2.2 Finite Element Model of Agonist Flux and Distribution
A two-dimensional model of fluid flow and agonist transport
was developed using commercial finite element software
(COMSOL Multiphysics, Burlington, MA). The model
geometry consists of two parallel channels, each with a height
of 100 μm and a length of 18.5 mm, connected by a
membrane at the half-length. The membrane was modeled as a
porous medium with a Darcy’s permeability of 3690 nm2
(Table 1). The fluid in the top layer had the density (1060 kg
m-3) and viscosity (0.004 Pa s) of whole blood19, but does not
account for the volume excluded by blood cells. The solution
in the bottom channel had the physical properties of water and
the diffusivity of ADP was estimated using the Wilke-Chang
correlation20.
The mesh consisted of 303,616 triangular elements. Mesh
independence was evaluated by comparing the concentration
profiles for grids consisting of 206,436, 303,616 and 375,122
elements. There was no greater than 2% difference in the
magnitude of the concentration between the three grid sizes at
any position within the simulation geometry. The steady state
mass and momentum conservation equations were solved in
28 minutes using a linear systems solver (UMFPACK) on a
Linux workstation (dual 2.2 GHz processors, 12 GB RAM).
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2.3 Device characterization
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2.3.1 Membrane hydraulic permeability
The hydraulic permeability for membranes with a pore
diameter of 0.6 μm and 1 μm and three surface conditions (no
coating, BSA coated, fibrinogen coated) was determined by
measuring the flow rate through the membrane under a
constant pressure head. Protein coatings were achieved by
incubation of 1 mg/ml BSA or 0.1 mg/ml fibrinogen for two
hours at room temperature followed by thorough rinsing in
deionized water. Wet membranes were mounted in a filter
holder (F0101-BA, Structure Probe Inc., West Chester, PA,
USA). A constant pressure head was provided in a 60 mL
syringe attached to the top of the filter holder. The flow rate
was determined by measuring the weight of the permeating
deionized water after 5 minutes on a top loading balance.
Water levels of 1.5, 2, and 2.5 inches of water (373, 500,
627 Pa) were maintained for 5 minutes for 0.6 μm
membranes. Water levels of 1.5, 2, and 3 inches of water
(373, 500, 750 Pa) were maintained for 5 minutes for 0.6 μm
membranes. Each measurement was performed in triplicate
with a different membrane.
These pressure drops are
comparable to those across the membrane within the device.
Using Darcy’s Law (v=k/μ∇P), the permeability was
calculated by a least square fit of the data Q/A versus P/t,
where Q is the flow rate in m3/s, A is the membrane area in
m3, P is the pressure drop in Pa, and t is the thickness in m.
This journal is © The Royal Society of Chemistry [year]
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Previous reports showed that water flux decreases with time
for track-etched polycarbonate membranes. In a second set of
experiments, we measured the permeability as function of
time over 25 minutes at each pressure (250, 500, 750 Pa).
2.3.2 Luciferase molar flux
The molar flux was adjusted by changing the wall shear rate
in the top channel, the relative flow rate (Q1/Q2), and agonist
concentration. We used firefly luciferase (61 kDa) as model
agonist and measured the flux through a polycarbonate
membrane with an average pore diameter of 1 μm. The flow
rate in the top channel was set to mean wall shear rates of
250, 500, 1000, and 2000 sec-1 to represent the range of
venous to arterial shear rates. The relative flow rate between
the top and bottom channel (Q1/Q2) was varied over a range
of 0.075-25. In experiments where Q1/Q2>1, fluid was
withdrawn from both channels. In experiments where
Q1/Q2<1, fluid was withdrawn from the top channel and
infused into the bottom channel. The fluid in the top channel
was 1 mg/mL bovine serum albumin (BSA) (Sigma, St. Louis,
MO) in phosphate buffered saline (PBS). The fluid in the
bottom channel was 1 nM or 10 nM luciferase and 1 mg/mL
BSA in PBS. The BSA helped minimize adsorption of the
luciferase to PDMS. Before each experiment the channels and
membrane were incubated in a 1 mg/mL BSA solution for one
hour to minimize nonspecific protein adsorption.
For each experiment, a total of 100 μL of fluid was
collected from the top channel. Following the experiment, 20
μL aliquots of fluid from both channels were transferred into
white 96-well plates in triplicate for each experimental
condition. Luciferase concentration was determined by flash
luminescence using a plate reader (2103 Envision,
PerkinElmer, Waltham, MA). An automated dispenser in the
plate reader injected each well with 100 μL of substrate
(E4550, Promega Corp., Madison, WI) followed immediately
by reading the luminescence signal for 10 seconds. Luciferase
concentration was calculated by integrating the luminescence
signal for nine seconds and comparing the integrated signal to
a standard curve. A standard curve was generated for each
plate over the linear range (10 fM to 1 nM) of the
luminescence assay. The luciferase flux was calculated by
multiplying the concentration by the flow rate and dividing by
the cross-sectional area (100 μm × 100 μm) where the two
channels intersect. Each experimental condition was run in
triplicate on a separate membrane.
Membranes used for protein filtration are known to foul
over time, which can lead to diminished water and solute
flux21, 22. We investigated the role of fouling in this system by
measuring luciferase flux at different transmembrane
pressures over 25 minutes. The experimental conditions were
1 nM luciferase and 1 mg/mL BSA in PBS in the bottom
channel, 1 mg/mL BSA in PBS in the bottom channel,
Q1/Q2=10 for mean wall shear rates of 2000 sec-1 and 1000
sec-1, Q1/Q2=0.5 for mean wall shear rates of 500 sec-1 and
250 sec-1 in the top channel. Fractions were collected every 5
minutes, diluted to a total volume of 100 μL, and the flux was
determined following the procedure above.
2.4 Introduction of ADP into flowing whole blood
Journal Name, [year], [vol], 00–00 | 3
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Human whole blood was obtained from healthy volunteers via
venipuncture and anticoagulated with sodium citrate (9 parts
blood to 1 part sodium citrate) and corn trypsin inhibitor (50
μg/ml final concentration) to block Factor XIIa and associated
intrinsic pathway initiation. Platelets were incubated for five
minutes
with
an
anti-CD41:Alexa
647
antibody
(MCU467A647, AbD Serotec, Releigh, NC) at a volume ratio
of 50 parts blood to 1 part antibody. Immediately before
introduction into the device, the blood was recalcified with
CaCl2 (100mM in HEPES buffered saline) to a final calcium
concentration of 20 mM. The blood was withdrawn to achieve
a mean wall shear rate of 250 sec-1 for five minutes. ADP (10
μM) in HEPES buffered saline (HBS) was perfused at relative
flow rates of Q1/Q2=0.075, 0.15, 0.3 corresponding to
transmembrane pressures of 1020, 545, and 308 Pa,
respectively. After five minutes, the blood was replaced with
HBS and the adhered platelets were washed for five minutes
at a mean wall shear rate of 100 sec-1. Each experimental
condition was run in triplicate with blood from a different
donor. The platelet count for each donor was measured using
a Coulter counter.
The device was operated as described in section 2.3.2,
except that the polycarbonate membrane was incubated in 0.1
mg/mL human fibrinogen for 2 hours. Adsorbed fibrinogen is
amenable to activated platelet adhesion through the αIIbβ3
integrin, but does not result in quiescent platelet adhesion at
the shear rates in this report23. Before introducing blood and
agonists into the device, the channels were filled with 1
mg/ml BSA solution in HBS buffer and allowed to flow for 10
minutes at Q1/Q2=1.
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2.5 Post hoc electron and confocal microscopy
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Immediately following a flow experiment, the device was
dismantled and the membrane was thoroughly washed in HBS
buffer. The sample was fixed in 2% glutaraldehyde for four
hours at room temperature and overnight at 4 ºC. The samples
were stored in 0.1 M sodium cacodylate buffer at 4 ºC until
processing. The day of imaging, the samples were dehydrated
for 15 minutes in graded ethanol solutions of 50%, 70%, 80%,
90%, and twice in 100%. For electron microscopy, the
samples were then critical point dried and sputtered with
Au/Pd. Samples were imaged on a field emission scanning
electron microscope (Supra 50VP, Carl Zeiss SMT,
Oberkochen, Germany) at an accelerating voltage of 5 kV. For
fluorescence microscopy, the samples were coverslipped in
mounting medium (H-100, Vector Laboratories, Burlingame,
CA) and imaged using a 60x oil immersion objective on a
spinning disk confocal fluorescence microscope (IX81-DSU,
Olympus America, Center Valley, PA).
To estimate the role of ADP flux on platelet aggregation,
we calculated the platelet surface and volume density in
aggregates for the different experimental conditions. For each
membrane, the integrated fluorescence intensity of single
platelets (n=10) was measured as a baseline value (Fo). The
integrated fluorescence intensity of each aggregate (Fa) was
divided by the baseline single platelet value to yield the
number of platelets per aggregate (N=Fa/Fo). We defined the
platelet surface density as the number of platelets per

4 | Journal Name, [year], [vol], 00–00

aggregate divided by the aggregate area ( N =N/Aa). We only
considered platelet aggregates formed in the first 200 μm
downstream from the reaction zone. The platelet volume
density within an aggregate was measured by dividing the
surface density by the confocal stack height, which ranged
from 4-8 μm.
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3.1 Device Characterization

A three layer device consisting of two perpendicular channels
and a membrane was fabricated for controlling the flux of
platelet agonists into blood flowing at physiological shear
rates (Figure 1). The three layers were reversibly sealed
during operation by vacuum-assisted bonding. The agonist
flux was a function of the membrane properties, the relative
flow rate of the two channels (Q1/Q2), and the agonist
concentration in the bottom channel.
3.1.1 Membrane hydraulic permeability
The
permeability
was
measured
for
track-etched
polycarbonate membranes with pore diameter of 0.6 and 1
μm. Table 1 shows the permeability of membranes with these
two pore diameters for no surface treatment, adsorbed BSA,
and adsorbed fibrinogen. Figure S1 shows the velocity as a
function of pressure and least squares fit used to determine
permeability. There is approximately a four-fold smaller
permeability of the 0.6 μm pore membranes than the 1.0 μm
pore membrane (k1μm/k0.6μm≈4). For a porous medium with
straight cylindrical pores, like track-etch polycarbonate, the
permeability is proportional to the pore density and the pore
diameter to the fourth power (k α N dpore4)24.
The
manufacturer reports a pore density of 2 × 107 pores/cm2 for 1
μm pore diameter membranes and 3 × 107 pores/cm2 for 0.6
μm pore diameter membranes. Therefore, the ratio of the
permeabilities between the two membranes should be
k1μm/k0.6μm=5.1. However, this estimate does not account for
dispersity of pore sizes and non-parallel pores, both of which
could lead to a lower permeability.
For a pore diameter of 1 μm there was no significant
change in the permeability for all three surface conditions.
There was a 43% decrease in permeability for fibrinogen
treated 0.6 μm pore membranes and no change for BSAtreated membranes. Based on these results, we chose to use
the 1 μm pore membranes for device characterization and
blood experiments since there was no change in permeability
between BSA and fibrinogen surface treatments.
Previous reports have shown a decrease in water flux with
time for track-etched polycarbonate membranes24, 25. Figure
S2 shows the decline in water flow rate for membranes with a
1 μm average pore diameter as function fo time. For constant
pressure heads of 250, 500, and 750 Pa there was a 11.0%,
10.5%, and 4.4% decline in water flux over 25 minutes,
respectively. The flux decline may be due to particulates in
the water and bubbles forming within the pores. Mueller and
Davis reported a 41-60% water flux decline in track-etched
polycarbonate membranesover the same time, albeit for
smaller pores (0.2 mm) and much larger pressures (69,000138,000 Pa)25.

This journal is © The Royal Society of Chemistry [year]

5

10

15

20

25

30

35

40

45

50

55

3.1.2 Luciferase molar flux
The agonist flux was manipulated by varying three
parameters; relative flow rate, wall shear rate, and agonist
concentration. Varying the relative flow rate and wall shear
rate were both methods for changing the pressure drop across
the membrane. Varying the agonist concentration changed the
concentration gradient between the two channels. Figure 2a
shows the luciferase flux as function of the relative flow rate
(Q1/Q2) for a mean wall shear rate of 1000 sec-1 and 2000
sec-1 in the top channel. The luciferase flux was modulated by
almost one order of magnitude at 2000 sec-1 by changing the
relative flow rate from 1 to 25. Decreasing the flow rate in the
bottom channel (agonist) to less than 10% of the flow rate in
the top channel results in negligible changes in agonist flux.
The analytical model qualitatively describes the trend
measured in the data, but tends to underestimate the agonist
flux by 10-20% at these wall shear rates.
Figure 2b shows the decline in luciferase flux as a function
of time for four wall shear rates. The mean wall shear rates
were 2000, 1000, 500, and 250 sec-1, which corresponded to
transmembrane pressures of 550, 275, 120, and 60 Pa. Over a
25 minute experiment there was an average luciferase flux
decline of 50% (550 Pa), 37% (275 Pa), 40% (120 Pa), and
49% (60 Pa). Mueller and Davis reported a 98% decline in
BSA flux (feed concentration 1 mg/mL) over the same time in
a 0.2 mm pore polycarbonate membrane for a transmembrane
pressure of 138,000 Pa25. Similar to our results, they did not
find the transmembrane pressure to affect the rate of fouling.
Figure 2c compares the experimental flux to the theoretical
flux (k=3690 nm2) from the analytical model developed in
Section 2.2.1. The flux depends linearly on transmembrane as
predicted by eqn. 6 for all times, however the model does not
describe the change in permeability as a function of time.
Since the percent decline was similar for all pressures, there
was significantly larger changes in the magnitude of the flux
at higher transmembrane pressures. This fact was most
evident at a transmembrane pressure of 550 Pa, the where
model underestimates flux at early times and overestimated
flux at late times.
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3.2 Platelet aggregation as a function of ADP flux

ADP (10 μM) was introduced at relative flow rates of 0.075,
0.15, and 0.3 into whole blood flowing at a mean wall shear
rate of 250 sec-1 over a fibrinogen coated membrane. These
relative flow rates correspond to ADP molar fluxes of 4.4, 2.4,
1.5 × 10-18 mol μm-2 sec-1 (eq. 6), respectively. Identical
experimental conditions using an ADP feed concentration fo 1
μM resulted in negligible platelet adhesion.
The adhesion and aggregation of platelets was monitored in
real-time using fluorescence microscopy (Figure 3). Imaging
through several layers of material (glass, PDMS, and
polycarbonate) diminished the resolution of images, but
nevertheless allowed for real-time monitoring of platelets
adehsion. Individual platelets were resolved at early times
(Figure 3a). A possible improvement of the device is to
replace the bottom PDMS layers with channels etched in
glass, thereby removing a layer and improving resolution.
Following the experiment, the membrane was removed

This journal is © The Royal Society of Chemistry [year]
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from the device and prepared for either electron or confocal
microscopy. Figure 4 demonstrates that the area and height of
platelet aggregates depends on ADP flux. There were no
platelet aggregates formed at the lowest ADP flux. Aggregates
of 20-250 platelets were observed at an ADP flux of 2.4 × 1018
mol μm-2 sec-1. These aggregates tended to be monolayers
and had a platelet surface density of 0.21±0.05 platelets μm-2
(n=24) and an average volume density of 5.22 × 107 platelets
μL-1. Aggregates of 75-1000 platelets were observed at an
ADP flux of 4.4 × 10-18 mol μm-2 sec-1. These aggregates
often contained multiple layers of platelets and had a platelet
surface density of 0.31±0.04 platelets μm-2 (n=11) and an
average volume density of 3.45 × 107 platelets μL-1. The
volume density of platelets within aggregates was 174 fold
and 115 fold greater than the average platelet plasma density
for an ADP flux of 4.4 × 10-18 mol μm-2 sec-1 and 2.4 × 10-18
mol μm-2 sec-1, respectively.
Observations from electron microscopy of aggregates show
that the morphology of platelets was qualitatively different at
a higher ADP flux (Figure 5). At the lowest ADP flux
(Q1/Q2=0.3), platelets adhered only to the 100 μm × 100 μm
reaction zone where the two channels intersected. In addition,
most of these platelets maintained their quiescent discoid
shape and did not form aggregates (Figure 5a). At the middle
ADP flux (Q1/Q2=0.15), platelet adhesion was not limited to
the reaction zone and aggregates were observed up to one
millimeter downstream from the reaction zone. The presence
of filopodia protruding from cell bodies and platelet-platelet
tethers clearly indicates activated platelets (Figure 5b).
The size and height of platelet aggregates increased with
increasing ADP flux as expected from consideration of the
ADP distribution in the top channel. A boundary layer of ADP
begins to form at the upstream edge of the membrane and
grows over the length of the membrane (Figure 6a).
Downstream from the membrane, the boundary layer begins to
dissipate by diffusion into the bulk solution. The thickness of
the boundary layer depends on the ADP flux through the
membrane. Figure 6b illustrates this dependence for the three
operating conditions considered in the ADP experiments. As
the flux increases, the thickness of the boundary layer
increases, and therefore more flowing platelets are activated
and aggregate. At the middle ADP flux (2.4 × 10-18 mol μm-2
sec-1) most of the aggregates were monolayers of platelets,
whereas at the high ADP flux (4.4 × 10-18 mol μm-2 sec-1)
there were several multilayer aggregates.

4 Discussion
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Platelet adhesion to surface-bound protein on the
subendothelium is the initial condition of blood coagulation.
Following adhesion, the platelets become activated and in turn
generate thrombin and thromboxane A2 on their extracellular
membranes and release ADP from intracellular stores to
promote further platelet activation and aggregation. The
release of these platelet agonists into the blood flowing over
the adhered platelets is the boundary condition that leads to
platelet aggregation. The flux of these three agonists into
flowing blood serves an important role in thrombosis and
hemostasis. However, the combined function of such soluble
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agonists during clot formation under flow is unknown, since
no method allows controlled fluxes of agonists into flowing
blood. The relationship between solute flux and stable clot
formation is a complex reaction-transport problem with
coupled particle deposition. One example of altered solute
flux is hemophilia, where deficiencies in clotting factors
attenuates thrombin generation26, which leads to unstable
clots27. It is less clear whether these clots are unstable because
of diminished fibrin formation or diminished platelet
activation, or both. The device described in this report
provides a method for manipulating solute flux that could be
useful for studying hemophilia and other bleeding disorders.
The size and growth of a thrombus is limited by the
interplay between activated platelets and intact endothelial
cells. Endothelial cells secrete soluble molecules (nitric
oxide, prostacyclin, ecto-necleotidases) that control platelet
reactivity in a process known as thromboregulation28. The
device presented in this report could be extended to study
thromboregulation with additional bottom channels for
introduction of these platelet antagonists.
Incorporation of membranes into microfluidic devices is
becoming increasingly common for on-chip filtration and
separations, as well as a component for sensors, reactors, and
cell culture29. In this report we incorporated commercially
available membranes as fluidic resistor into a microfluidic
device by modifying a technique first reported by Ismagilov
and colleagues30. This technique has been employed for
screening biochemical interaction30, generating chemical
gradients31, and monitoring communication between different
cell types32. A notable modification we have made was the use
of vacuum assisted bonding33. This reversible bonding
technique allowed for post hoc morphological analysis of
platelet aggregates by electron and spinning disk confocal
microscopy.
Track-etched polycarbonate membranes demonstrate both
internal and external fouling under different operating
conditions24, 25, 34. Internal fouling describes the adsorption
and deposition of molecules and particles onto the surface of
the pore, and consequently reducing the pore size. External
fouling describes the accumulation of larger particles and
cells that cannot enter pores. We have chosen a membrane
whose pores are much larger than any of the solutes we are
interested in introducing into blood, but also small enough to
exclude blood cells. However, we still observed fouling of the
pores that lead to significant flux decline over 25 minutes.
This flux decline was most likely the result of internal fouling
based on moderate transmembrane pressures and short length
of the experiments25. Other choices of membranes include
cellulose acetate, polyvinylidene fluoride, or polysulfone.
However, these other membranes have a minimum thickness
on the order of 100’s microns, whereas the polycarbonate
membranes are 5-15 μm thick. The membrane thickness is an
important parameter in the multilayer device described in the
manuscript.
We attempted to use a cellulose acetate
membrane (thickness=110 μm) and found that the loss of fluid
into
the
vacuum
chamber
was
prohibitive.
Solute transport was accurately predicted with an analytical
model when convection was the dominant transport
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mechanism within the pores (Pe>10). Although the model did
not account for protein fouling, it was a good first-order
etstimate of flux that only required two parameters, the
membrane permeability and transmembrane pressure. The
device was operated in two configurations that depended on
the wall shear rate in the top channel. At higher wall shear
rates (1000-2000 sec-1), there was a large enough
transmembrane pressure generated by the top channel to
achieve predominantly convective transport in the pores. At
these high shear rates, fluid was withdrawn (negative
pressure) from both channels. At lower wall shear rates (250500 sec-1), the transmembrane pressure generated by the top
channel was insufficient to ensure convective transport.
Therefore, at these low shear rates, the bottom channel was
infused (positive pressure) to compensate for small pressure
drop in the top channel. In some applications, such as gradient
generation, diffusion-mediated transport may be preferable.
This mode of operation is achievable by withdrawing fluid
from both channels at the same flow rate, provided the
channels have the same length and cross-sectional area.
As a demonstration of the device, we examined the
dependence of platelet aggregation on ADP flux. We observed
that platelet activation, aggregation size, and aggregation
height depended on the magnitude of ADP flux. At the lowest
ADP flux considered, there was sparse adhesion of platelets
and little evidence of aggregation and platelet-platelet
tethering. At the higher fluxes, we observed aggregates of
hundreds of activated platelets. The size and height of
aggregates increased with increasing ADP flux. These
observations agree with previous reports that platelet adhesion
efficiency to fibrinogen coated surfaces increases with ADP
induced activation23. In addition, computational studies
predict that a thicker agonist boundary layer yields greater
platelet aggregation35-37. In these computational studies,
boundary layer thickness and thus platelet aggregation was
modulated by changing the wall shear rate. However,
increasing the agonist flux has a similar effect to decreasing
the wall shear rate.

5 Conclusions

100

105

We have fabricated and characterized a membrane-based
microfluidic device for controlling the flux of platelet agonists
into flowing blood. The molar flux of luciferase was
accurately predicted at high pore Peclet numbers using an
analytical model. The introduction of ADP (1.5-4.4 × 10-18
mol μm-2 sec-1) into flowing whole blood resulted in flux
dependent platelet aggregation and activation. We expect this
device will be a useful tool in unraveling the role of platelet
agonists on clot formation and stability.
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Table 1 The Darcy’s permeability was measured for track-etched
polycarbonate membranes with an average pore diameter of 0.6 μm and 1
μm for three surface treatments; no treatments, incubation in 1 mg/mL
bovine serum albumin (BSA), incubation in 0.1 mg/mL fibrinogen. The
permeability values were calculated by a least squares fit of water
velocity as a function of pressure drop across the membrane for three
transmembrane pressures (Figure S1). The goodness-of-fit was measured
by the R2 statistic.

a

Treatment

Pore Diameter
(μm)

Darcy’s Permeabilitya
(nm2)

R2

No coating
BSA
Fibrinogen

1
1
1

3720
3530
3690

0.97
0.90
0.90

No coating
BSA
Fibrinogen

0.6
0.6
0.6

905
965
519

0.97
0.97
0.90

See Figure S1 for velocity versus pressure data.
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Fig. 1 (a) The device consisted of two perpendicular channels in PDMS separated by a polycarbonate membrane. The two PDMS layers are reversibly
sealed using vacuum assisted bonding. (b) At the intersection of the two channels, the flux of the agonist molecules was controlled by the pore size and
transmembrane pressure. The transmembrane pressure was manipulated by varying the relative flow rate (Q1/Q2) between the top and bottom channels.
(c) Electron micrograph of the bottom channel and posts in the vacuum chamber, which provided mechanical support during operation.
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Fig. 2 (a) For the mean wall shear rates of 1000 sec-1 and 2000 sec-1 in the
top channel, the flux was manipulated by changing the relative flow rate
(Q1/Q2). The flow rate in the top channel, Q1, was held constant to
achieve a desired wall shear rate, and Q2 was changed to vary the
transmembrane pressure. The solid lines represent the luciferase flux
predicted by eqn. 6. (b) The luciferase flux decreased with time due to
fouling of the pores for wall shear rates of 250, 500, 1000, and 2000 sec-1.
(c) The flux data in (b) plotted as function of transmembrane pressure,.
The line represents the predicted for a Darcy’s permeability of 3690 nm2.
Each data point represents the mean and the error bars represent the
standard deviation (n=3).
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Fig. 3 Real-time fluorescence microscopy of platelet adhesion and
aggregation for a mean wall shear rate of 250 sec-1, 10 μM ADP in the
bottom channel, and Q1/Q2=0.075 at (a) 1, (b) 3, and (c) 5 minutes.
Scale bar=50 μm.
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Fig. 4 Spinning disk confocal images (a-c) and volume reconstruction (d-f) of platelet aggregates formed by introducing ADP into flowing whole blood at
a defined flux. (a,d) At the highest flux (4.4 × 10-18 mol μm-2 sec-1), there were 2-3 layers of platelets and aggregates with 7a surface density of 0.31±0.04
platelets μm-2. (b,e) At the middle flux (2.4 × 10-18 mol μm-2 sec-1) there were monolayers of platelets and aggregates with a surface density of 0.21±0.05
platelets μm-2. (c,f) At the lowest flux (1.5 × 1010-18 mol μm-2 sec-1), no aggregates were observed, but there was platelet adhesion within the reaction
zone. Scale bar=10 μm (a-c) and grid spacing=5 μm (d-f).

12 | Journal Name, [year], [vol], 00–00

This journal is © The Royal Society of Chemistry [year]

5

Fig. 5 Electron microscopy of adhered and aggregated platelets at the
reaction zone. (a) At the lowest ADP flux (Q1/Q2=0.3), platelets adhered
in singlets or small aggregates (2-5 cells). (b) At the higher ADP flux
(Q1/Q2=0.15), platelets had multiple filopodia protruding from their cell
bodies and formed aggregates. Scale bar=5 μm.
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Fig. 6 : (a) Simulation of the boundary layer formed when ADP (Q1/Q2=0.15) was introduced into whole blood flowing at a wall shear rate of 250 sec-1.
(b) The simulation predicts that the thickness of the boundary layer increases with increasing ADP flux. The ADP concentration was plotted as a function
of vertical distance, represented by the white line in (a), and relative flow rate at the edge of the reaction zone.
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Fig S1 The hydraulic permeability of track-etched polycarbonate membranes was determined by a least squares fit of the velocity versus pressure drop
(eqn. 5). Surface treatments of BSA and fibrinogen did not affect the permeability of membranes with a pore diameter of 1 μm. Fibrinogen treatment, but
not BSA treatment, resulted in a decrease in permeability of membranes with a pore diameter of 0.6 μm.
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Fig. S2 The water flux through a track-etched polycarbonate membrane with a pore diameter of 1 mm. For constant pressure heads of 250, 500, and 750
Pa there was a 11.0%, 10.5%, and 4.4% decline in water flux over 25 minutes.
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This report describes a membrane-based method for controlling the flux of soluble agonists into flowing blood. The device allows
for real-time measurements of cellular adhesion and aggregation, as well as post hoc microscopy for examining aggregate
morphology.
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